It depends on the standard you follow. As of September 2026, Amgen Inc. (AMGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 23.3% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.70% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 23.3% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.70% / 33% · Receivables / Mkt Cap (36m) 4.47% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 23.3% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.70% / 33.33% · Receivables / Mkt Cap (24m) 4.47% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 59.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 12.9% / 33.33% · Receivables / Avg Assets (4Q) 10.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 56.2% / 33.33% · (Cash+ST Inv) / Total Assets 13.7% / 33.33% · (Cash+Recv) / Total Assets 24.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Amgen Inc. (AMGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Amgen Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Amgen Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Amgen Inc. (NASDAQ: AMGN) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $250.1B. The Maz Rating grades it against the other companies in its sector.
Amgen Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $462.32, Amgen Inc. trades at 26.6x trailing earnings, 6.4x sales and 17.4x book value, with an EV/EBITDA of 16.0. Over the last twelve months it generated about $38.9B of revenue and $9.4B of net income. It runs a gross margin of 71.7%, an operating margin of 32.4% and a net margin of 24.1%. It shows return on equity of 85.6%, return on invested capital of 14.2% and a free cash flow yield of 3.8%. On the balance sheet: a debt-to-equity ratio of 3.76 and a current ratio of 1.48. Over the past 52 weeks the share price ranged from $312.39 to $483.99, with a beta of 0.42.
Amgen Inc. pays a dividend yielding 2.15%, with 57% of earnings paid out. Its Maz Dividend Score is 2.97 out of 5, ranked against the other dividend payers in its sector (Safety 1.77, Growth 3.97, Yield 4.10, Consistency 3.41).
41 Wall Street analyst ratings cover the stock: 21 Buy, 17 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.